outcomes & healthcare utilization cost of patients with cll refractory to btk and bcl-2 inhibitors
Published 1 year ago • 43 plays • Length 2:25Download video MP4
Download video MP3
Similar videos
-
1:27
advances in btk and bcl2 inhibitors for cll
-
1:19
outcomes of cll patients following treatment with a covalent btk and bcl2 inhibitor
-
1:53
clinical outcomes of btki ven treatment in cll/sll: double-exposed vs double-refractory patients
-
1:24
sequencing of btk inhibitors in cll
-
1:32
genomic evolution & resistance to pirtobrutinib in covalent btk inhibitor pre-treated cll
-
1:46
preclinical efficacy of the pkcβ inhibitor ms-553 in btki resistant cll
-
7:56
hydroxyproline assay kit ii protocol | biovision, inc.
-
3:35
epigenomics in precision oncology
-
7:28
1 year post hsct :)
-
1:08
phase i/ii bruin study: pirtobrutinib in patients intolerant to a covalent btk inhibitor
-
2:53
considering the sequencing of covalent and non-covalent btk inhibitors in cll
-
1:13
dual-targeted regimens for the treatment of cll: anti-cd20 antibodies, btki, and bcl2i
-
0:49
the future of inhibiting bcl2 for the treatment of t-all
-
3:36
outcomes of patients with newly diagnosed crlf2-rearranged b-all
-
3:03
the evolution of treatment patterns and prognostic biomarkers in latin american cll patients
-
2:52
acquired mutations associated with resistance to btki in patients with cll
-
1:14
predicting patient response to btk inhibitors using novel approaches
-
1:50
real-world outcomes of teclistamab treatment in r/r multiple myeloma
-
1:21
improved clinical outcomes in cll when switching from covalent btki to a bcl2i following intolerance
-
8:57
outcomes of sct in t-all and t-lbl
-
5:02
a retrospective study of venetoclax re-treatment in cll patients
-
1:12
patient-reported outcomes in hsct